The Effectiveness of Trivalent Inactivated Influenza Vaccine in Children with Acute Leukemia

Overview

Journal J Pediatr

Specialty Pediatrics

Date 2017 Nov 28

PMID 29173310

Citations 7

Authors

April Sykes

Elsie Gerhardt

Li Tang

Elisabeth E Adderson

Affiliations

Soon will be listed here.

Abstract

Objective: The objective of this study was to determine the effectiveness of trivalent inactivated influenza vaccine (TIV) for the prevention of laboratory-confirmed influenza and influenza-like illnesses (ILI) among children and adolescents receiving therapy for acute leukemia.

Study Design: A retrospective review of the demographic and clinical characteristics of 498 patients at a pediatric cancer center who received therapy for acute leukemia during 3 successive influenza seasons (2010-2011 through 2012-2013).

Results: In 498 patient seasons with a known immunization history (median age, 6 years; range, 1-21), 354 patients (71.1%) were immunized with TIV and 98 (19.7%) received a booster dose of vaccine. Vaccinated and unvaccinated patients had generally similar demographic characteristics. There were no differences in the overall rates of influenza or ILI between vaccinated and unvaccinated patients overall, or in any individual season. There was no difference in the rates of influenza or ILI between patients who received 1 dose of vaccine and those who received 2 doses. Time to first influenza infection and time to first ILI in vaccinated and unvaccinated patients were not different.

Conclusion: TIV did not protect children and adolescents with acute leukemia against laboratory-confirmed influenza or ILI. Future prospective studies should assess TIV effectiveness in high-risk subpopulations and alternative strategies to prevent influenza should be considered in this population.

Citing Articles

[Efficacy and safety of pediatric flu vaccination: a systematic review].

Escandell Rico F, Perez Fernandez L Rev Esp Quimioter. 2023; 37(1):43-51.

PMID: 38050694 PMC: 10874658. DOI: 10.37201/req/101.2023.

Assessment of the Prevalence of Infections in Pediatric Patients With Acute Lymphoblastic Leukemia.

Nair A, Elballushi R, Joshi R, Anjanappa S, Akter M, Arif S Cureus. 2023; 15(10):e46837.

PMID: 37954717 PMC: 10636770. DOI: 10.7759/cureus.46837.

Neutropenia and Infection Prophylaxis in Childhood Cancer.

Villeneuve S, Aftandilian C Curr Oncol Rep. 2022; 24(6):671-686.

PMID: 35230594 PMC: 8885776. DOI: 10.1007/s11912-022-01192-5.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.

Maus M, Alexander S, Bishop M, Brudno J, Callahan C, Davila M J Immunother Cancer. 2020; 8(2).

PMID: 33335028 PMC: 7745688. DOI: 10.1136/jitc-2020-001511.

Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant.

Hijano D, Maron G, Hayden R Front Microbiol. 2019; 9:3097.

PMID: 30619176 PMC: 6299032. DOI: 10.3389/fmicb.2018.03097.

References

Thompson M, Naleway A, Fry A, Ball S, Spencer S, Reynolds S . Effects of Repeated Annual Inactivated Influenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010-11. Vaccine. 2016; 34(7):981-8. PMC: 5218812. DOI: 10.1016/j.vaccine.2015.10.119. View

Quinn H, Snelling T, Habig A, Chiu C, Spokes P, McIntyre P . Parental Tdap boosters and infant pertussis: a case-control study. Pediatrics. 2014; 134(4):713-20. DOI: 10.1542/peds.2014-1105. View

Choi D, Fuleihan R, Walterhouse D . Serologic response and clinical efficacy of influenza vaccination in children and young adults on chemotherapy for cancer. Pediatr Blood Cancer. 2016; 63(11):2011-8. DOI: 10.1002/pbc.26110. View

Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G . Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 2011; 30(12):1081-5. DOI: 10.1097/INF.0b013e3182367662. View

McCullers J, Huber V . Correlates of vaccine protection from influenza and its complications. Hum Vaccin Immunother. 2012; 8(1):34-44. DOI: 10.4161/hv.8.1.18214. View

Ottoffy G, Horvath P, Muth L, Solyom A, Garami M, Kovacs G . Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy. Pediatr Blood Cancer. 2014; 61(6):1013-6. DOI: 10.1002/pbc.24893. View

Kempe A, Hall C, MacDonald N, Foye H, Woodin K, Cohen H . Influenza in children with cancer. J Pediatr. 1989; 115(1):33-9. DOI: 10.1016/s0022-3476(89)80325-7. View

Chiu C, Openshaw P . Antiviral B cell and T cell immunity in the lungs. Nat Immunol. 2014; 16(1):18-26. PMC: 7097128. DOI: 10.1038/ni.3056. View

Wang K, Shun-Shin M, Gill P, Perera R, Harnden A . Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev. 2012; 1:CD002744. DOI: 10.1002/14651858.CD002744.pub3. View

10.

Carr S, Adderson E, Hakim H, Xiong X, Yan X, Caniza M . Clinical and demographic characteristics of seasonal influenza in pediatric patients with cancer. Pediatr Infect Dis J. 2012; 31(11):e202-7. PMC: 3473140. DOI: 10.1097/INF.0b013e318267f7d9. View

11.

Bodewes R, Fraaij P, Osterhaus A, Rimmelzwaan G . Pediatric influenza vaccination: understanding the T-cell response. Expert Rev Vaccines. 2012; 11(8):963-71. DOI: 10.1586/erv.12.69. View

12.

Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R . Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol. 2010; 10:18. PMC: 2851702. DOI: 10.1186/1471-2288-10-18. View

13.

. Update: influenza activity - United States, 2011-12 season and composition of the 2012-13 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2012; 61(22):414-20. View

14.

Goossen G, Kremer L, van de Wetering M . Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database Syst Rev. 2013; (8):CD006484. PMC: 6466690. DOI: 10.1002/14651858.CD006484.pub3. View

15.

Okoli G, Otete H, Beck C, Nguyen-Van-Tam J . Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies. PLoS One. 2014; 9(12):e113633. PMC: 4260958. DOI: 10.1371/journal.pone.0113633. View

16.

Freedman J, Reilly A, Powell S, Bailey L . Quality improvement initiative to increase influenza vaccination in pediatric cancer patients. Pediatrics. 2015; 135(2):e540-6. DOI: 10.1542/peds.2014-0943. View

17.

Hakim H, Allison K, Van de Velde L, Li Y, Flynn P, McCullers J . Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults. Vaccine. 2011; 30(5):879-85. DOI: 10.1016/j.vaccine.2011.11.105. View

18.

Shehata M, Karim N . Influenza vaccination in cancer patients undergoing systemic therapy. Clin Med Insights Oncol. 2014; 8:57-64. PMC: 4011725. DOI: 10.4137/CMO.S13774. View

19.

. Recommendations for Prevention and Control of Influenza in Children, 2016-2017. Pediatrics. 2016; 138(4). DOI: 10.1542/peds.2016-2527. View

20.

Kotecha R, Wadia U, Jacoby P, Ryan A, Blyth C, Keil A . Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer. Cancer Med. 2015; 5(2):285-93. PMC: 4735770. DOI: 10.1002/cam4.596. View